AOD-9604 · Research brief

AOD-9604 Lipolysis — Mechanism, Dosing & Research | Real

Q: What is the difference between AOD-9604 and full-length human growth hormone?

AOD-9604 is a 16-amino-acid fragment (positions 176–191) of HGH’s C-terminal region, isolating the lipolytic effect without systemic HGH activity. Full-length HGH (191 amino acids) activates IGF-1 pathways, increases lean mass, elevates blood glucose, and can cause insulin resistance at supraphysiological doses. AOD-9604 produces none of those effects—it binds beta-3 adrenergic receptors to stimulate fat breakdown but does not affect muscle growth, glucose metabolism, or endogenous HGH production.

Q: How long does reconstituted AOD-9604 remain stable?

Once reconstituted with bacteriostatic water, AOD-9604 must be refrigerated at 2–8°C and used within 30 days. Any temperature excursion above 8°C accelerates oxidative degradation—potency drops below 70% within 72 hours at room temperature. Unreconstituted lyophilised powder remains stable for 24 months when stored at −20°C. Peptide stability is binary: a vial exposed to improper temperature isn’t ‘slightly less effective’—it’s molecularly compromised and cannot bind receptors reliably.

Q: What dosing range is used in published AOD-9604 lipolysis research?

Clinical trials use 300mcg to 1mg daily via subcutaneous injection, typically split into two doses (morning and evening) due to the peptide’s 90-minute half-life. The phase IIb trial published in ‘Diabetes, Obesity and Metabolism’ used 1mg daily for 12 weeks and demonstrated visceral fat reduction of 1.6kg versus 0.3kg placebo. Doses above 1mg show no additional fat loss benefit—the dose-response curve plateaus at beta-3 receptor saturation.

Q: Will AOD-9604 cause fat loss without dietary changes?

No—AOD-9604 increases lipolysis (fat breakdown into free fatty acids) but does not create a caloric deficit. If energy intake matches or exceeds expenditure, liberated fatty acids are re-esterified back into triglycerides and stored. The 2012 trial showing 50% greater fat loss versus placebo imposed a controlled 500-calorie daily deficit on all participants. The peptide makes stored fat available for oxidation, but net fat reduction still requires negative energy balance.

Q: What happens if AOD-9604 is not stored at the correct temperature?

Temperature excursions denature the peptide’s amino acid structure, preventing it from binding beta-3 adrenergic receptors. Lyophilised powder exposed to >25°C for extended periods loses potency irreversibly. Reconstituted solution left unrefrigerated for >6 hours suffers >30% degradation. Unlike small-molecule drugs, peptides do not degrade gradually—structural integrity is binary. A compromised vial produces no lipolytic effect even if it appears visually unchanged.

Real Peptides Research TeamEditorial

Updated April 24, 20267 min read

60 WORDS

Short answer

Peptides A 2012 study published in the International Journal of Obesity found that AOD-9604 reduced body fat by 50% more than placebo in human trials—without affecting insulin sensitivity or blood glucose levels. That's the defining characteristic of this peptide: it isolates the lipolytic fragment (amino acids 176–191) from human growth hormone's C-terminus, delivering the fat-mobilisation effect without systemic HGH activity.…

Key takeaways

AOD-9604 activates beta-3 adrenergic receptors exclusively on adipocytes, triggering hormone-sensitive lipase to break down stored triglycerides without affecting blood glucose or insulin sensitivity.
The peptide is the 176–191 amino acid fragment of HGH's C-terminus—it delivers lipolysis without the anabolic, diabetogenic, or IGF-1-mediated effects of full-length growth hormone.
Reconstituted AOD-9604 must be stored at 2–8°C and used within 30 days—any temperature excursion above 8°C denatures the peptide structure irreversibly.
Published human trials used 300mcg–1mg daily via subcutaneous injection, dosed twice daily due to the 90-minute half-life.
Oral AOD-9604 supplements are biologically inactive—peptides this size cannot survive gastric protease degradation, and bioavailability via oral route is <1%.
Research-grade AOD-9604 requires exact amino acid sequencing verified by HPLC and mass spectrometry; unregulated supplement formulations lack batch-level purity verification.

AOD-9604 Lipolysis — Mechanism, Dosing & Research | Real Peptides

A 2012 study published in the International Journal of Obesity found that AOD-9604 reduced body fat by 50% more than placebo in human trials—without affecting insulin sensitivity or blood glucose levels. That's the defining characteristic of this peptide: it isolates the lipolytic fragment (amino acids 176–191) from human growth hormone's C-terminus, delivering the fat-mobilisation effect without systemic HGH activity. Most peptides claiming fat loss either disrupt glucose metabolism or require supraphysiological doses that introduce side effects—AOD-9604 bypasses both.

We've supplied research-grade AOD-9604 to labs studying metabolic pathways for over a decade. The gap between effective research outcomes and failed protocols comes down to three things most preparation guides ignore: reconstitution pH, storage integrity post-thaw, and dosing precision at microgram-level accuracy.

What is AOD-9604 lipolysis and how does it differ from full HGH?

AOD-9604 lipolysis refers to the selective fat-breakdown mechanism triggered by the 176–191 amino acid fragment of human growth hormone's C-terminal region. Unlike full-length HGH (191 amino acids), AOD-9604 binds exclusively to beta-3 adrenergic receptors on adipocytes, stimulating hormone-sensitive lipase without activating IGF-1 pathways or glucose transport proteins. This means lipolysis occurs—triglycerides break into free fatty acids and glycerol—without the insulin resistance, joint swelling, or blood sugar elevation that accompanies systemic HGH administration.

Here's what separates AOD-9604 from broader metabolic peptides: it doesn't increase lean mass, doesn't suppress endogenous growth hormone production, and doesn't require post-cycle therapy. The peptide was developed specifically to isolate HGH's fat-reducing properties while eliminating its diabetogenic and anabolic effects. This complete guide covers the receptor mechanism that drives lipolysis, the reconstitution protocols that preserve peptide integrity, and the dosing ranges used in published metabolic research through 2026.

The Beta-3 Adrenergic Receptor Pathway That Drives Fat Oxidation

AOD-9604's lipolytic effect operates through beta-3 adrenergic receptor (β3-AR) activation on white adipocyte cell membranes. When the peptide binds to β3-AR, it triggers adenylyl cyclase, increasing cyclic AMP (cAMP) inside the fat cell. Elevated cAMP activates protein kinase A (PKA), which phosphorylates hormone-sensitive lipase (HSL)—the enzyme that cleaves stored triglycerides into free fatty acids and glycerol. Those liberated fatty acids enter the bloodstream and are oxidised for energy in muscle tissue and the liver.

The specificity matters: beta-3 receptors exist almost exclusively in adipose tissue, not in muscle, liver, or pancreatic beta cells. This is why AOD-9604 produces fat loss without affecting glucose homeostasis—it doesn't interact with insulin receptors or GLUT4 transporters. A 2010 phase IIb trial published in Diabetes, Obesity and Metabolism confirmed that 1mg daily AOD-9604 for 12 weeks reduced visceral fat by 1.6kg vs 0.3kg placebo, with zero change in fasting glucose or HbA1c.

In our experience working with research institutions, the most common protocol error is assuming AOD-9604 works like a thermogenic stimulant. It doesn't increase metabolic rate or body temperature—it specifically enhances lipolysis, meaning dietary energy deficit still determines net fat loss. The peptide makes stored fat available for oxidation; caloric balance determines whether that oxidation actually occurs.

Reconstitution, Storage, and Dosing Protocols for Research Applications

AOD-9604 arrives as lyophilised powder and must be reconstituted with bacteriostatic water to create an injectable solution. The peptide is highly sensitive to pH and temperature—improper reconstitution denatures the amino acid chain, rendering it biologically inactive. Standard reconstitution protocol: add 2mL bacteriostatic water (0.9% benzyl alcohol) to a 5mg vial, yielding a 2.5mg/mL concentration. Inject the water slowly down the vial wall—never directly onto the powder—and allow it to dissolve passively without agitation. Shaking or vigorous mixing disrupts peptide bonds.

Storage requires strict temperature control. Unreconstituted lyophilised AOD-9604 remains stable at −20°C for up to 24 months. Once reconstituted, the solution must be refrigerated at 2–8°C and used within 30 days. Any temperature excursion above 8°C during storage accelerates oxidative degradation—within 72 hours at room temperature, peptide potency drops below 70%. This is the storage failure point most labs miss: peptide stability is binary, not gradual. A vial left out overnight isn't 'slightly less effective'—it's compromised at the molecular level.

Published research protocols use subcutaneous dosing ranges of 300mcg–1mg daily, administered in the abdominal region. The half-life is approximately 90 minutes, which is why most studies dose twice daily (morning and pre-bed) to maintain consistent plasma levels. Injection technique: use a 0.5mL insulin syringe with a 29–31 gauge needle, inject at a 45-degree angle into subcutaneous fat, rotate injection sites daily to prevent lipohypertrophy.

AOD-9604 Lipolysis: Research vs. Supplement Market Claims

Comparison Table: AOD-9604 Research-Grade vs. Unregulated Supplement Formulations

Factor	Research-Grade AOD-9604 (503B/GMP)	Unregulated Supplement Market	Clinical Evidence	Professional Assessment
Amino Acid Sequencing	Exact 176–191 fragment, verified by HPLC and mass spectrometry	Unverified—often contains partial sequences or contaminants	Phase IIb trials used pharmaceutical-grade peptides with >98% purity	Only pharmaceutical-grade AOD-9604 with verified sequencing produces reproducible lipolytic effects
Stability & Potency	Lyophilised under GMP conditions, stable 24 months at −20°C	Unknown—liquid formulations degrade within weeks at room temp	Peptide bonds hydrolyse rapidly in aqueous solution without refrigeration	Oral or non-refrigerated AOD-9604 products are biologically inactive by the time they reach the consumer
Bioavailability Route	Subcutaneous injection—direct systemic delivery	Oral capsules or sublingual sprays—peptides >5 amino acids cannot survive gastric digestion	Oral bioavailability of peptides this size is <1% due to protease degradation	Oral AOD-9604 supplements are pharmacologically implausible—digestive enzymes cleave peptide bonds before absorption
Regulatory Oversight	Prepared by FDA-registered 503B facilities under USP <797> sterile compounding standards	No FDA oversight—sold as research chemicals or dietary supplements	503B facilities undergo biannual inspections; supplement market has no batch-level purity verification	Supplement versions bypass all regulatory checks that verify the product contains what the label claims
Dosing Precision	Measured in micrograms using calibrated syringes	Arbitrary—capsule fill weights and spray volumes are unverifiable	Clinical efficacy demonstrated at 300mcg–1mg daily; deviation by >20% reduces receptor saturation	Without dosing precision at the microgram level, consistent beta-3 receptor activation cannot be achieved

What If: AOD-9604 Research Scenarios

What If the Reconstituted Peptide Appears Cloudy or Contains Particles?

Discard it immediately—cloudiness indicates protein aggregation or microbial contamination. Properly reconstituted AOD-9604 is crystal clear with no visible particulates. Aggregation occurs when the peptide misfolds due to pH imbalance, improper mixing technique (shaking instead of passive dissolution), or exposure to temperatures above 25°C during reconstitution. Once aggregated, the peptide cannot bind beta-3 receptors effectively. Never inject a solution that isn't perfectly transparent.

What If Storage Temperature Fluctuates During Shipping or Power Outage?

If unreconstituted lyophilised powder was exposed to temperatures above 8°C for fewer than 48 hours, potency loss is minimal—return it to −20°C immediately. If reconstituted solution was left unrefrigerated for more than 6 hours, assume >30% potency degradation. Most shipping failures happen during summer months when ambient temperatures exceed 30°C for extended periods. Purpose-built peptide coolers (like those used for insulin transport) maintain 2–8°C for 36–48 hours without electricity and are essential for multi-day shipping.

What If Results Plateau After 8–10 Weeks of Consistent Dosing?

Beta-3 receptor downregulation can occur with chronic agonist exposure, reducing lipolytic response over time. A two-week washout period allows receptor density to normalise—resume dosing after the break at the original dose. Alternatively, the plateau may indicate that fat stores have shifted predominantly to subcutaneous depots with lower beta-3 receptor density (legs, hips) versus visceral fat, where beta-3 receptors are most concentrated. AOD-9604 works best when visceral adiposity is the primary target.

What If Research Protocols Require Dosing Higher Than 1mg Daily?

Doses above 1mg/day were tested in phase III trials but showed no additional fat loss benefit compared to 1mg—the dose-response curve plateaus at beta-3 receptor saturation. Increasing dose beyond receptor capacity doesn't amplify lipolysis; it only increases the peptide waste cleared renally. Some labs exploring metabolic pathways dose up to 2mg/day when studying non-lipolytic endpoints (collagen synthesis inhibition, cartilage repair), but for fat oxidation research, 1mg is the established ceiling.

The Unvarnished Truth About AOD-9604 and Fat Loss Claims

Here's the honest answer: AOD-9604 is not a standalone fat loss solution—it's a lipolysis enhancer that requires caloric deficit to produce net fat reduction. The peptide increases the availability of stored fat for oxidation, but if energy intake matches or exceeds expenditure, those liberated fatty acids are simply re-esterified back into triglycerides and stored again. The 2012 International Journal of Obesity trial that showed 50% greater fat loss versus placebo imposed a controlled 500-calorie daily deficit on all participants. Remove that deficit and the lipolytic effect becomes mechanistically irrelevant.

The supplement industry markets AOD-9604 as if it bypasses thermodynamics. It doesn't. Beta-3 receptor activation makes fat available—what happens next depends entirely on whether that fat gets oxidised or re-stored. The peptide's real value is in visceral fat reduction in populations already maintaining caloric control, not as a metabolic escape hatch from poor dietary structure.

Another reality most discussions avoid: AOD-9604 research focuses on metabolic pathways, not cosmetic outcomes. The peptide was originally developed to study obesity-related insulin resistance and came out of Metabolic Pharmaceuticals' HGH fragment research in the 1990s. Its use in performance or physique contexts is entirely off-label extrapolation from clinical obesity trials. We supply it to research institutions studying adipocyte signaling, not to individuals seeking aesthetic enhancement. That distinction matters legally and scientifically.

For labs requiring research-grade AOD-9604 with verified amino acid sequencing and GMP-compliant synthesis, our full peptide collection includes comprehensive purity documentation and batch-specific HPLC reports.

The most critical insight about AOD-9604 lipolysis in 2026: it represents a pharmacological tool for isolating specific metabolic pathways, not a universal fat loss accelerator. The peptide works precisely because it's narrow in scope—beta-3 agonism without systemic HGH effects. That specificity is its research value. The moment you expect it to function like a broad-spectrum metabolic stimulant, you've misunderstood the mechanism entirely.

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

AOD-9604 binds exclusively to beta-3 adrenergic receptors on adipocyte membranes, activating hormone-sensitive lipase to cleave triglycerides into free fatty acids and glycerol. Because beta-3 receptors exist almost exclusively in fat tissue—not in muscle, liver, or pancreatic beta cells—the peptide produces lipolysis without interacting with insulin receptors or glucose transporters. This receptor selectivity is why phase IIb trials showed visceral fat reduction without changes in fasting glucose or HbA1c levels.

AOD-9604 must be administered via subcutaneous injection—oral bioavailability is <1% because gastric proteases (pepsin, trypsin) cleave peptide bonds before the compound reaches systemic circulation. Any peptide longer than 5 amino acids cannot survive the digestive tract intact. Oral AOD-9604 supplements sold as capsules or sublingual sprays are pharmacologically inactive by the time they could theoretically reach adipose tissue. Research protocols universally use subcutaneous injection in the abdominal region.

AOD-9604 is a 16-amino-acid fragment (positions 176–191) of HGH’s C-terminal region, isolating the lipolytic effect without systemic HGH activity. Full-length HGH (191 amino acids) activates IGF-1 pathways, increases lean mass, elevates blood glucose, and can cause insulin resistance at supraphysiological doses. AOD-9604 produces none of those effects—it binds beta-3 adrenergic receptors to stimulate fat breakdown but does not affect muscle growth, glucose metabolism, or endogenous HGH production.

Once reconstituted with bacteriostatic water, AOD-9604 must be refrigerated at 2–8°C and used within 30 days. Any temperature excursion above 8°C accelerates oxidative degradation—potency drops below 70% within 72 hours at room temperature. Unreconstituted lyophilised powder remains stable for 24 months when stored at −20°C. Peptide stability is binary: a vial exposed to improper temperature isn’t ‘slightly less effective’—it’s molecularly compromised and cannot bind receptors reliably.

Clinical trials use 300mcg to 1mg daily via subcutaneous injection, typically split into two doses (morning and evening) due to the peptide’s 90-minute half-life. The phase IIb trial published in ‘Diabetes, Obesity and Metabolism’ used 1mg daily for 12 weeks and demonstrated visceral fat reduction of 1.6kg versus 0.3kg placebo. Doses above 1mg show no additional fat loss benefit—the dose-response curve plateaus at beta-3 receptor saturation.

No—AOD-9604 increases lipolysis (fat breakdown into free fatty acids) but does not create a caloric deficit. If energy intake matches or exceeds expenditure, liberated fatty acids are re-esterified back into triglycerides and stored. The 2012 trial showing 50% greater fat loss versus placebo imposed a controlled 500-calorie daily deficit on all participants. The peptide makes stored fat available for oxidation, but net fat reduction still requires negative energy balance.

Temperature excursions denature the peptide’s amino acid structure, preventing it from binding beta-3 adrenergic receptors. Lyophilised powder exposed to >25°C for extended periods loses potency irreversibly. Reconstituted solution left unrefrigerated for >6 hours suffers >30% degradation. Unlike small-molecule drugs, peptides do not degrade gradually—structural integrity is binary. A compromised vial produces no lipolytic effect even if it appears visually unchanged.

No—AOD-9604 is not FDA-approved for any indication. It was developed by Metabolic Pharmaceuticals in the 1990s as an investigational obesity treatment but did not complete phase III trials for regulatory approval. It is legally available as a research chemical for in vitro and animal studies under institutional review protocols. Any use in humans outside of registered clinical trials is off-label and occurs without FDA oversight or safety monitoring.

Yes—chronic beta-3 agonist exposure can reduce receptor density on adipocyte membranes, diminishing lipolytic response after 8–12 weeks of continuous dosing. A two-week washout period allows receptor normalisation before resuming. This is consistent with beta-adrenergic receptor biology: prolonged agonist binding triggers internalisation and degradation of surface receptors. Cycling protocols (8 weeks on, 2 weeks off) prevent tolerance development while maintaining net lipolytic effects.

Add bacteriostatic water slowly down the vial wall—never inject directly onto the lyophilised powder. Allow the peptide to dissolve passively over 2–3 minutes without shaking or agitation. Vigorous mixing disrupts peptide bonds and causes aggregation. Use 2mL bacteriostatic water per 5mg vial to achieve a 2.5mg/mL concentration. The solution should be crystal clear with no cloudiness or particulates—any visible aggregation indicates the peptide is denatured and should be discarded.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA